HMGA2 Contributes to Distant Metastasis and Poor Prognosis by Promoting Angiogenesis in Oral Squamous Cell Carcinoma.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
19 May 2019
Historique:
received: 29 04 2019
revised: 17 05 2019
accepted: 18 05 2019
entrez: 22 5 2019
pubmed: 22 5 2019
medline: 7 11 2019
Statut: epublish

Résumé

The highly malignant phenotype of oral squamous cell carcinoma (OSCC), including the presence of nodal and distant metastasis, reduces patient survival. High-mobility group A protein 2 (HMGA2) is a non-histone chromatin factor that is involved in advanced malignant phenotypes and poor prognosis in several human cancers. However, its biological role in OSCC remains to be elucidated. The purpose of this study was to determine the clinical significance and role of HMGA2 in the malignant potential of OSCC. We first investigated the expression pattern of HMGA2 and its clinical relevance in 110 OSCC specimens using immunohistochemical staining. In addition, we examined the effects HMGA2 on the regulation of vascular endothelial growth factor (VEGF)-A, VEGF-C, and fibroblast growth factor (FGF)-2, which are related to angiogenesis, in vitro. High expression of HMGA2 was significantly correlated with distant metastasis and poor prognosis. Further, HMGA2 depletion in OSCC cells reduced the expression of angiogenesis genes. In OSCC tissues with high HMGA2 expression, angiogenesis genes were increased and a high proportion of blood vessels was observed. These findings suggest that HMGA2 plays a significant role in the regulation of angiogenesis and might be a potential biomarker to predict distant metastasis and prognosis in OSCC.

Identifiants

pubmed: 31109142
pii: ijms20102473
doi: 10.3390/ijms20102473
pmc: PMC6566167
pii:
doi:

Substances chimiques

HMGA2 Protein 0
HMGA2 protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Japan Society for the Promotion of Science
ID : JP16K20595 and JP18H03005

Références

J Dent Educ. 2001 Nov;65(11):1282-90
pubmed: 11765876
Cancer Res. 2004 Mar 15;64(6):2024-9
pubmed: 15026339
J Cell Biol. 2006 Jul 17;174(2):175-83
pubmed: 16831886
Cancer Cell. 2006 Sep;10(3):227-39
pubmed: 16959614
Mol Carcinog. 2007 Jul;46(7):503-11
pubmed: 17477356
Nat Rev Cancer. 2007 Jun;7(6):415-28
pubmed: 17508028
Nat Rev Cancer. 2007 Dec;7(12):899-910
pubmed: 18004397
Cancer. 2008 May 1;112(9):2088-100
pubmed: 18327819
Cell. 2008 Dec 12;135(6):1013-6
pubmed: 19070572
Am J Pathol. 2009 Mar;174(3):854-68
pubmed: 19179606
Semin Cancer Biol. 2009 Oct;19(5):329-37
pubmed: 19482086
J Clin Invest. 2009 Jun;119(6):1420-8
pubmed: 19487818
Int J Cancer. 2009 Nov 1;125(9):2159-65
pubmed: 19569190
Biochim Biophys Acta. 2009 Dec;1796(2):293-308
pubmed: 19683560
Mod Pathol. 2010 May;23(5):673-81
pubmed: 20228781
Mol Hum Reprod. 2011 Feb;17(2):135-42
pubmed: 20926602
Clin Cancer Res. 2011 Apr 15;17(8):2570-80
pubmed: 21252160
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Mol Biol Rep. 2012 Feb;39(2):1239-46
pubmed: 21598109
J Oncol. 2012;2012:358472
pubmed: 22131994
Cell. 2012 Jan 20;148(1-2):349-61
pubmed: 22265420
Circ Res. 2013 Jan 4;112(1):152-64
pubmed: 23072816
Curr Opin Oncol. 2013 Jan;25(1):76-84
pubmed: 23197193
Tumour Biol. 2013 Oct;34(5):3165-71
pubmed: 23737289
Science. 2013 Nov 8;342(6159):1234850
pubmed: 24202173
Nat Rev Mol Cell Biol. 2014 Mar;15(3):178-96
pubmed: 24556840
Cancer Lett. 2014 Dec 1;355(1):130-40
pubmed: 25218351
Curr Opin Cell Biol. 2014 Dec;31:56-66
pubmed: 25240174
BMC Cancer. 2014 Sep 23;14:694
pubmed: 25245141
Nucleic Acids Res. 2015 Jan;43(1):162-78
pubmed: 25492890
Front Med (Lausanne). 2015 Mar 25;2:15
pubmed: 25859543
Otolaryngol Head Neck Surg. 2015 Jun;152(6):1053-60
pubmed: 25883102
Sci Rep. 2015 Jul 03;5:11689
pubmed: 26138061
J Clin Diagn Res. 2015 Jun;9(6):XE01-XE05
pubmed: 26266204
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
J Transl Med. 2016 Jan 27;14:26
pubmed: 26818837
Carcinogenesis. 2016 May;37(5):511-21
pubmed: 26964871
J Craniomaxillofac Surg. 2016 Sep;44(9):1422-9
pubmed: 27421171
Anticancer Res. 2017 Apr;37(4):1891-1899
pubmed: 28373457
Mol Cell Biol. 2017 Jul 28;37(16):null
pubmed: 28584193
Histopathology. 2019 Jan;74(2):311-320
pubmed: 30129658
Cell Death Dis. 2019 Jan 10;10(1):31
pubmed: 30631040

Auteurs

Junki Sakata (J)

Department of Oral and Maxillofacial Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan. j.sakata0510@gmail.com.

Akiyuki Hirosue (A)

Department of Oral and Maxillofacial Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan. ahiro711@kumamoto-u.ac.jp.

Ryoji Yoshida (R)

Department of Oral and Maxillofacial Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan. ryoshida@kumamoto-u.ac.jp.

Kenta Kawahara (K)

Department of Oral and Maxillofacial Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan. k.k.ronbun@gmail.com.

Yuichiro Matsuoka (Y)

Department of Oral and Maxillofacial Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan. kokopelli205@gmail.com.

Tatsuro Yamamoto (T)

Department of Oral and Maxillofacial Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan. tatsuro.y.1.3@gmail.com.

Masafumi Nakamoto (M)

Department of Oral and Maxillofacial Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan. mabo.20jd.jm@gmail.com.

Masatoshi Hirayama (M)

Department of Oral and Maxillofacial Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan. dd104040@gmail.com.

Nozomu Takahashi (N)

Department of Oral and Maxillofacial Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan. n.takahashi6074@gmail.com.

Takuya Nakamura (T)

Department of Oral and Maxillofacial Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan. takuyanakamura2008@gmail.com.

Hidetaka Arita (H)

Department of Oral and Maxillofacial Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan. hidetaka.arita@gmail.com.

Hikaru Nakashima (H)

Department of Oral and Maxillofacial Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan. ricken_hikaru@yahoo.co.jp.

Masashi Nagata (M)

Department of Oral and Maxillofacial Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan. nagatama0213@gmail.com.

Akimitsu Hiraki (A)

Section of Oral Oncology, Department of Oral and Maxillofacial Surgery, Fukuoka Dental College, Fukuoka 814-0193, Japan. hiluckyhilucky@gmail.com.

Masanori Shinohara (M)

Department of Oral and Maxillofacial Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan. shinora@kumamoto-u.ac.jp.

Hideki Nakayama (H)

Department of Oral and Maxillofacial Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan. hinakaya@kumamoto-u.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH